Home > Pressrelease > Proteomics Market size to surpass $128Bn by 2032

Proteomics Market size to surpass $128Bn by 2032

  • Published Date: November 9, 2022

Proteomics Market size is expected to reach USD 128 billion by 2032, as per a new research report announced by Global Market Insights Inc.

Increasing government support for healthcare R&D is one of the major factors boosting proteomic analysis research. The Center for Biologics Evaluation and Research, for example, evaluates the efficacy and safety of biological products associated with proteomics by regulating their approvals. The U.S. FDA is also engaged in examining the use of analytical proteomic tools to characterize biological products and validate biomarkers.

With the rapid rise of health research in disease treatment and diagnosis, the adoption of proteomics techniques will surge in developed countries including the UK. In March 2022, the NHS announced funding worth USD 290 million to enhance healthcare research efforts.  Approximately USD 223 million of this was committed to supporting NHS-led research in treatment & diagnostics, while the remaining USD 67 million was earmarked for life sciences manufacturing in the United Kingdom.

Proteomics services gain traction in complex biological system experiments

Proteomics market from the service component segment is set to exhibit over 13.5% CAGR through 2032. During complex biological system experiments, proteomics software services are used extensively to simplify the statistical analysis of data and add biological meaning. These services are also being leveraged to store complex, HRAM (high-resolution accurate-mass) Orbitrap data and can convert these datasets into valuable results. These attributes are contributing to the growing use of proteomic services in complex applications.

Browse key industry insights spread across 250 pages with 305 market data tables & 20 figures & charts from the report, “Proteomics Market Analysis By Component (Instruments, Consumables, Services), By Technique (Advanced Technique {Mass Spectrometry, Gel-based Technique, Protein Microarray}, Conventional Technique {ELISA, Chromatography-based Technique, Edman Sequencing, Western Blotting}, Bioinformatics Analysis), By Application (Clinical Diagnosis, Clinical Research), By End-use (Pharmaceutical & Biopharmaceutical Companies, Academic & Research Institute, Laboratories), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2023 – 2032” in detail along with the table of contents:

Rise of ELISA and chromatography techniques to fuel molecular & cellular proteomics study

Conventional technique segment accounted for over 32% share of the proteomics industry in 2022. This technique is further classified into ELISA, edman sequencing, chromatography-based technique, and western blotting. ELISA and chromatography techniques are gaining massive popularity to employ one or more inherent characteristics of an isoelectric point, protein-its mass, hydrophobicity, or bio-specificity. The report cites that these factors will promote molecular and cellular proteomics using conventional techniques.

Emphasis on diagnostic technique automation to boost proteomics use in clinical diagnosis

Proteomics market from clinical diagnosis segment held over 45% business share in 2022. The shift towards automation of laboratories is emerging as a prominent trend for clinical diagnosis facilities. In addition, the requirement for cost-effective sample analysis platforms has also surged. The report claims that these factors, along with the strong demand for diagnostic technique automation, are encouraging manufacturers to develop innovative proteomics products for use in clinical diagnosis applications.

R&D spending for product development augments proteomics demand in pharma sector

Proteomics market value from the pharmaceutical and biopharmaceutical segment was over USD 23 billion in 2022. Pharma and biopharma companies have been making investments in novel drug developments. For instance, in 2021, the members of the Pharmaceutical Research and Manufacturers of America invested close to USD 102.3 billion in R&D for new medication. This continued investment has led to novel drug development, transforming the health of patients with diseases including chronic conditions. Such investments will further encourage drug developers to accelerate their research and rely on proteomics services to further drive the product demand.

Increase in clinical trials to foster proteomics research in Latin America

Latin America proteomics market is projected to depict over 9% CAGR through 2032. Due to the established regulatory environment and advanced healthcare infrastructure, the region is emerging as one of the global hubs for conducting clinical trials and research. Based on statistics from OECD, in Brazil, health spending is slated to rise to 12.6% of GDP by 2040, a significant increase from 9.6% in 2019. These factors will contribute to the growth of healthcare research in various fields including proteomics, contributing to regional industry expansion.

Mergers & acquisitions to remain a key growth strategy for proteomics market participants

Seer, Inc, Biognosys AG, Creative Proteomics, SomaLogic Operating Co., Inc, Agilent Technologies, Inc, Promega Corporation, Thermo Fisher Scientific, Bruker, Bio-Rad Laboratories, Quantum-Si, Inc, PREOMICS GMBH, and Olink are some of the companies profiled in the report. These market players are focusing on strategies such as mergers and acquisitions to reinforce their presence in the global industry.

Authors: Sumant Ugalmugle, Rupali Swain